| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $2,698,900 | 3 | 100 |
Sells | $0 | 0 | 0 |
| Bellini Roberto | director | 1 | $2M | 0 | $0 | $2M |
| Munshi Amit | director | 1 | $500,050 | 0 | $0 | $500,050 |
| Kush Arvind | director | 1 | $198,650 | 0 | $0 | $198,650 |
Inhibikase Therapeutics, Inc., a clinical stage pharmaceutical company, develops therapeutics for Parkinson's Disease (PD) and related disorders that arise inside and outside of the brain. The company's product candidates include IkT-148009, a small molecule Abelson tyrosine kinase inhibitor for use in the treatment of PD, as well as gastrointestinal complications that arise as early symptoms of PD, such as swallowing, dysphagia, neurogenic constipation, and multiple system atrophy; and IkT-001Pro, a prodrug of the anti-cancer agent Imatinib that is in preclinical development to minimize gastrointestinal side effects and for the treatment of blood and stomach cancers. It is also involved in developing various research programs for other neurological diseases. The company has research and development collaborations with The Johns Hopkins University, Arizona State University, and Michigan State University, as well as Louisiana State University. Inhibikase Therapeutics, Inc. was founded in 2008 and is headquartered in Atlanta, Georgia.
Over the last 12 months, insiders at Inhibikase Therapeutics, Inc. have bought $2.7M and sold $0 worth of Inhibikase Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Inhibikase Therapeutics, Inc. have bought $920,960 and sold $0 worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bellini Roberto (director) — $2M. Munshi Amit (director) — $500,050. Kush Arvind (director) — $198,650.
The last purchase of 1,460,000 shares for transaction amount of $2M was made by Bellini Roberto (director) on 2024‑10‑21.
| 2024-10-21 | Bellini Roberto | director | 1.46M 12.071% | $1.37 | $2M | +1.35% | ||
| 2024-10-21 | Munshi Amit | director | 365,000 3.0178% | $1.37 | $500,050 | +1.35% | ||
| 2024-10-21 | Kush Arvind | director | 145,000 1.1988% | $1.37 | $198,650 | +1.35% | ||
| 2022-08-16 | Werner Milton H. | President and CEO | 5,000 0.0198% | $0.80 | $4,000 | -18.09% | ||
| 2022-05-27 | Werner Milton H. | President and CEO | 5,000 0.0207% | $0.98 | $4,880 | -21.09% | ||
| 2022-05-20 | Werner Milton H. | President and CEO | 10,000 0.0362% | $0.60 | $6,000 | +14.09% | ||
| 2022-05-19 | FRATTAROLI JOSEPH | Chief Financial Officer | 3,948 0.016% | $0.64 | $2,543 | +18.78% | ||
| 2021-11-17 | Werner Milton H. | President and CEO | 23,589 0.0935% | $1.97 | $46,558 | -51.43% |
| Bellini Roberto | director | 1460000 1.9639% | $2.69M | 1 | 0 | |
| Munshi Amit | director | 365000 0.491% | $671,600.00 | 1 | 0 | |
| Kush Arvind | director | 145000 0.195% | $266,800.00 | 1 | 0 | |
| Werner Milton H. | President and CEO | 5335433 7.1769% | $9.82M | 4 | 0 | <0.0001% |
| FRATTAROLI JOSEPH | Chief Financial Officer | 48091 0.0647% | $88,487.44 | 1 | 0 | +18.78% |
$5,558,275 | 76 | -5.88% | $154.94M | |
$48,218,096 | 42 | 0.89% | $125.2M | |
$18,752,549 | 33 | -28.39% | $148.62M | |
$294,424,120 | 20 | 1.33% | $129.54M | |
$1,351,643 | 19 | 46.45% | $142.67M | |
$111,692,551 | 18 | 13.51% | $142.68M | |
$448,999,793 | 15 | -19.99% | $135.53M | |
$73,968,137 | 12 | -34.52% | $135.06M | |
$9,999,920 | 10 | -40.03% | $128.37M | |
$1,073,250 | 10 | 19.46% | $125.66M | |
$13,043,783 | 8 | 732.82% | $150.2M | |
$22,090,972 | 7 | -3.49% | $132.51M | |
$478,647 | 7 | 69.41% | $124.34M | |
$68,692,148 | 6 | -39.10% | $124.17M | |
Inhibikase Therapeutics, Inc. (IKT) | $63,981 | 5 | -11.55% | $136.79M |
$32,289,200 | 3 | -5.46% | $158.99M | |
$9,999,990 | 2 | 25.53% | $137.77M | |
$300,016 | 1 | -50.33% | $136.83M | |
$5,512,500 | 1 | -7.91% | $139.97M |
| Increased Positions | 31 | +124% | 2M | +4.59% |
| Decreased Positions | 6 | -24% | 892,621 | -1.78% |
| New Positions | 19 | New | 1M | New |
| Sold Out Positions | 3 | Sold Out | 43,303 | Sold Out |
| Total Postitions | 50 | +100% | 51M | +2.8% |
| Sands Capital Ventures, Llc | $24,638.00 | 14.8% | 10.95M | +11M | New | 2024-12-31 |
| Soleus Capital Management, L.P. | $14,231.00 | 8.55% | 6.33M | +6M | New | 2024-12-31 |
| Fairmount Funds Management Llc | $13,781.00 | 8.28% | 6.13M | +6M | New | 2024-12-31 |
| Commodore Capital Lp | $13,331.00 | 8.01% | 5.92M | +6M | New | 2024-12-31 |
| Perceptive Advisors Llc | $13,331.00 | 8.01% | 5.92M | +6M | New | 2024-12-31 |
| Adar1 Capital Management, Llc | $11,482.00 | 6.9% | 5.1M | +5M | New | 2024-12-31 |
| Vanguard Group Inc | $6,387.00 | 3.84% | 2.84M | +3M | +16,873.48% | 2024-12-31 |
| Nantahala Capital Management, Llc | $4,928.00 | 2.96% | 2.19M | +2M | New | 2024-12-31 |
| Blackstone Inc. | $4,659.00 | 2.8% | 2.07M | +2M | New | 2024-12-31 |
| Stonepine Capital Management, Llc | $2,548.00 | 1.53% | 1.13M | +1M | New | 2024-12-31 |